US FDA cites Bayer for Yaz TV commercial violations
This article was originally published in Scrip
Executive Summary
Two television commercials forBayer Healthcare's Yaz (drospirenone plus ethinylestradiol) broaden the oral contraceptive’s indication, overstate its efficacy and minimise risks, the US FDAhas said in a warning letter.
You may also be interested in...
US FDA Aims For More Timely Reviews Of Rx Drug Launch Promotions
New review process planned to launch next year. FDA officials and industry reps note re-emergence of FDA enforcement actions targeting internet-sponsored links.
Drug Shortages, Inspections In Focus At US FDA Appropriations Hearing
Commissioner Robert Califf discussed the agency’s request for $12.3m to address shortages and legislation to require that manufacturers provide more detailed information about increased demand and supply chain vulnerabilities.
Clinical Trial Diversity Requires Sponsors Work With An Assortment Of Patient Advocates, Community Organizations
US FDA oncology officials are concerned that the entities sponsors are consulting in developing and implementing clinical trial diversity plans are not sufficiently diverse themselves and do not represent patients in underserved communities.